, 3 Direction of Research and Innovation, Centre Oscar Lambret, 3 rue Combemale, 59020 Lille cedex, France. 4 Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France. 5 Department of Medical Oncology, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94800 Villejuif, France. 6 Department of Medical Oncology, Centre René Gauducheau, 13009.
, 11 Department of Clinical Research and Innovation, p.59020
,
Angiosarcoma: state of the art and perspectives, Crit Rev Oncol Hematol, vol.80, pp.257-63, 2011. ,
Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome, Ann Oncol, vol.23, pp.517-540, 2012. ,
European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.102-114, 2014. ,
Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face, Hum Pathol, vol.41, pp.407-421, 2010. ,
Efficacy of Tie2 receptor antagonism in angiosarcoma, Neoplasia, vol.14, pp.131-171, 2012. ,
Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas, J Surg Oncol, vol.97, pp.74-81, 2008. ,
MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF upregulation in angiosarcomas, Am J Pathol, vol.153, pp.1425-1458, 1998. ,
Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas, Mod Pathol, vol.13, pp.180-185, 2000. ,
KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors, Cancer Res, vol.69, pp.7175-7184, 2009. ,
Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo, American J Pathol, vol.156, pp.1469-76, 2000. ,
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma, American J Pathol, vol.156, pp.2179-83, 2000. ,
The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets? Lung Cancer, vol.65, pp.49-55, 2009. ,
Recurrent PTPRB and PLCG1 mutations in angiosarcoma, Nat Genet, vol.46, pp.376-385, 2014. ,
Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial, J Clin Oncol, vol.33, pp.2797-802, 2015. ,
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from phase II trial, Target Oncol, vol.9, pp.273-280, 2014. ,
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas, Ann Oncol, vol.24, pp.257-63, 2013. ,
, Alliance A091103 a phase II study of the angiopoietin, vol.1
, peptibody trebananib for the treatment of angiosarcoma, Cancer Chemother Pharmacol, vol.75, pp.629-667, 2015.
A phase 1B/ phase 2A study of TRC105 (Endoglin antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissuesarcoma (STS) ,
, J Clin Oncol, vol.34, p.11016, 2016.
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas, Cancer, vol.118, pp.3330-3336, 2012. ,
Cytokine and angiogenic factors associated with efficacy and toxicity in advanced soft tissue sarcomA: an EORTC STBSG study, Br J Cancer, vol.107, pp.659-704, 2012. ,
Circulating biomarkers in advanced colorectal patients randomly assigned to three bevacizumab-based regimens, Cancer, vol.6, pp.1753-68, 2014. ,
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma, Oncologist, vol.17, pp.1063-72, 2012. ,
Dynamic contrastenhanced magnetic resonance imaging as a surrogate biomarker for bevacizumab in colorectal cancer liver metastasis: a single-arm exploratory trial, Cancer Res Treat, vol.48, pp.1210-1231, 2016. ,
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proc Natl Acad Sci U S A, vol.112, pp.1547-52, 2015. ,
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevaciazumab schedule in metastatic colorectal cancer, Br J Cancer, vol.104, pp.1262-1271, 2011. ,
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance, J Clin Oncol, vol.28, pp.453-462, 2010. ,